Search page

Comparison of Component Resolved Diagnosis (CRD) with skin prick test in respiratory allergy [36 cases] and Significance of CRD in Anaphylaxis [8 cases] & Chronic Urticaria with/ without Angioedema [16 cases]

Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Correlation of chronic rhinosinusitis and lung function in allergy patients with chronic cough

Correlation of chronic urticaria and angioedema with the presence of Helicobacter pylori infection

Cost Of Illness Analysis of Chronic Urticaria in 5 Latin American Countries: Diagnostic and Therapeutic Expenses

Descriptive Study of Chronic Urticaria Under Treatment with Omalizumab: Our Experience

Do air pollution and weather affect chronic urticaria attack frequency?

Effect of Remibrutinib on Disease Activity in Patients with Chronic Spontaneous Urticaria: Post Hoc Analysis of Phase 3 REMIX-1 and REMIX-2 studies

Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 Studies

Emerging treatments for chronic urticaria

Evaluation of Serum Arginase-1 Levels in Chronic Urticaria

Evaluation of Serum IL-35 Level in Patients with Chronic Spontaneous Urticaria: A case control study

Exploring Drug Hypersensitivity in Pediatric Patients with Chronic Spontaneous Urticaria: ‘’A Comprehensive Analysis Using Diagnostic Tests”

How can we improve the approach to treating chronic urticaria in children?

IgE anti-TPO; from acute to chronic urticaria

Impact of chronic urticaria on the quality of life of patients followed up at a university hospital Nis-Serbia

Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H1-Antihistamine Treatment

Knowledge and satisfaction about the use of Patient Reported Outcomes Measures (PROMs) by patients with chronic urticaria

MOLECULAR IgE SENSITIZATION PROFILE IN A PATIENT WITH ADULT ATOPIC DERMATITIS AND CHRONIC URTICARIA SYNDROME TO FOODS

Management chronic urticaria in children

New players in chronic urticaria

Novartis – Chronic spontaneous urticaria (CSU): The Patient Experience

Omalizumab and chronic spontaneous urticaria: ‘one dose does not fit all’

Predicting Responses to Omalizumab in Antihistamine-Refractory Chronic Urticaria

Quality of life of families with children suffering from chronic urticaria

Real-World Evaluation of Omalizumab in Chronic Spontaneous and Inducible Urticaria: A Longitudinal Analysis during 15 years from a Lisbon UCARE

Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies

Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study

SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis

Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies

Serum Cytokine Profiles in Chronic Spontaneous Urticaria: Correlations with Disease Severity, Endotypes, and Autoreactivity

Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria

Successful administration of omalizumab following anaphylaxis in a patient with chronic idiophatic urticaria

Systemic Histaminergic Findings in Children with Chronic Urticaria

The UCARE Study on the Prevalence of Sleep Disorders and Nighttime Bruxism in People with Chronic Urticaria

The association between baseline IgE levels and response to standard-dose omalizumab in uncontrolled chronic urticaria patients

The challenge of chronic urticaria management

The characteristics of Chronic Inducible Urticaria in Cape Town, South Africa

The correlation between chronic rhinosinusitis with/without nasal polyp and chronic kidney disease: a longitudinal follow-up study

Treatment with Omalizumab in chronic spontaneous urticaria: experience in a tertiary hospital

Update on chronic inducible urticaria

What to examine when you consider chronic urticaria

What’s new in chronic urticaria management?

When Antihistamines Paradoxically Worsen Chronic Spontaneous Urticaria: Trust Your Patient

A Comparison of Chronic Spontaneous Urticaria Presentation in Canadian and Israeli Adults

A novel approach of pooling donors for basophil testing to diagnose type 2 autoimmune chronic spontaneous urticaria

A randomized, double-blind, phase 2a study of covalent Bruton’s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines

A retrospective analysis of patients with chronic spontaneous urticaria in treatment with Omalizumab conducted in Brescia

Analysis of discontinuation of omalizumab in patients with chronic spontaneous and/or inducible urticaria in a tertiary hospital in one year

Assessing Post-Earthquake Living Conditions and Quality of Life in Chronic Spontaneous Urticaria Patients: Container houses vs. pre-existing buildings

Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial

Beneficial role of Psychotherapeutic Interventions in Managing Chronic Spontaneous Urticaria Refractory to Omalizumab – A Case Study

Benralizumab in Omalizumab refractory chronic spontaneous urticaria – A Case Series of 4 Patients in Portugal

Beyond the Rash: How Omalizumab Shapes Mental Health Outcomes in Chronic Spontaneous Urticaria

Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis

Biomarkers in chronic spontaneous urticaria

Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from a Phase 1b/2a Study

Celldex – Shining a Light on Mast Cells in Chronic Spontaneous Urticaria

Characterization of pathomechanisms of acute and chronic spontaneous urticaria

Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Chronic Spontaneous Urticaria Patients in Latvia: Epidemiological and Clinical Characteristics

Chronic Spontaneous Urticaria and its relationship with Allergies to Aerogenic Fungi: dermographism, skin hyperreactivity, and chemical patterns of inflammation

Chronic spontaneous urticaria in Japan: real-world prevalence, treatments and healthcare resource utilisation based on a health insurance database

Chronic spontaneous urticaria in children: Series of 10 cases

Chronic spontaneous urticaria with wheals, angioedema, or both: Differences in clinical characteristics, biomarkers and treatment response

Comparable Efficacy and Pharmacodynamic Results of CT-P39 to Reference Omalizumab in Patients with Chronic Spontaneous Urticaria

Comparative Efficacy and Safety of Omalizumab Intended copy Biosimilar vs. Biologic in Chronic Spontaneous Urticaria

Comparison of baseline clinical characteristics of chronic spontaneous urticaria patients receiving omalizumab, with and without concomitant angioedema

Demographic and Laboratory Differences Between Chronic Spontaneous and Chronic Inducible Urticaria: Insights from a Lisbon UCARE

Detailed Clinical Characterization of a Large Cohort of Chronic Spontaneous Urticaria Patients

Diet modification recommendation for Chronic Spontaneous Urticaria patients -Albanian Allergists approach

Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Efficacy and safety of switching to bilastine, a histamine H1 receptor antagonist, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a phase IV, multicenter, open-label, randomized, parallel-group comparative controlled trial

Efficacy and safety of therapy with omalizumab in children with chronic spontaneous urticaria

Efficacy of Omalizumab in Food Allergy Management in a Patient with Chronic Spontaneous Urticaria

Evaluation of Real-World Mental Health and Sleep Outcomes Over Time in US Patients With Chronic Spontaneous Urticaria

Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Exploring potential predictive factors for time to response to Omalizumab treatment in a Romanian subset of patients with Chronic Spontaneous Urticaria

Gain-of-function mutations of human MRGPRX2 in the Chronic spontaneous urticaria

Hidden parasitic causes in chronic spontaneous urticaria

Hives and hidden codes: detection of miRNA in chronic spontaneous urticaria patients – pilot study

IgE and Eosinophils levels may predict Successful Omalizumab withdrawal in chronic spontaneous urticaria

IgG and IgE autoantibodies in chronic spontaneous urticaria

Impact of chronic inducible urticaria (CIndU) on patients’ health-related quality of life: Results from Urticaria Voices study

Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Increased eosinophil-derived neurotoxin levels in serum of chronic spontaneous urticaria patients

Investigating Autoimmunity in Chronic Spontaneous Urticaria : The astonishing association

Knowledge, attitudes and practice patterns in chronic spontaneous urticaria management among Italian General Practitioners: Baseline data from the BRIDGE implementation science study

LAD2 Mast Cell Activation Test in Chronic Spontaneous Urticaria

Long-Term Efficacy and Safety of Remibrutinib in Patients with Chronic Spontaneous Urticaria in the Phase 3 REMIX-1 and REMIX-2 Studies

MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Management of Chronic Spontaneous Urticaria and Atopic Dermatitis with Omalizumab: A Case Report Highlighting Efficacy and Emerging Challenges

Minimal persistent inflammation in chronic spontaneous urticaria patients with clinical remission

Next generation sequencing analysis in H1-antihistamine-refractory chronic spontaneous urticaria

Phenotypic Clusters of Patients with Severe Chronic Spontaneous Urticaria

Physicians’ prescribing patterns and perceptions of treatments for chronic spontaneous urticaria: Real world data from Urticaria Voices

Poorly controlled chronic spontaneous urticaria is associated with significant clinical, humanistic, and economic burden

Potential blood biomarkers of disease activity in patients with chronic spontaneous urticaria

Predictive role of peripheral blood Plasma MRGPRX2 expression to the response of anti-histamine treatment in the Chronic spontaneous urticaria patients

Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Reduction in Weekly Urticaria Activity Score (UAS7) With Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies

Rilzabrutinib Reduces IgG Anti-Thyroid Peroxidase (anti-TPO), Soluble Mas-Related G Protein-Coupled Receptor X2 (sMRGPRX2) and Eosinophils at 12 Weeks in Patients With Chronic Spontaneous Urticaria

Rupatadine treatment improves disease control in patients with chronic spontaneous urticaria – results from the CURE registry

SEP-631: A Novel Selective and Potent Oral MRGPRX2 Inhibitor for the Treatment of Chronic Spontaneous Urticaria

Sustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Taking a closer look to the first EMA-approved omalizumab biosimilar in Chronic Spontaneous Urticaria

Taming the Unpredictable: Omalizumab’s Role in Idiopathic anaphylaxis and chronic spontaneous urticaria

The BEACON Study: A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of the c-Kit Mab Briquilimab in Adults with symptomatic Chronic Spontaneous Urticaria (CSU)

The Urticaria Voices study: Experiences and unmet needs of patients with chronic inducible urticaria (CIndU)

The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study

Treatment of Chronic Spontaneous Urticaria with Omalizumab Complicated by Onychodystrophy?

Treatment of Chronic Spontaneous Urticaria with Omalizumab during Pregnancy- Experience in a Portuguese Ucare

Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Chronic Spontaneous Urticaria (CSU) patients: Results from 52 Weeks of Treatment

Urticaria exacerbations in children with chronic urticaria receiving COVID-19 vaccination

A predictive model to differenciate chronic histaminergic angiodema and chronic spontaneous urticaria with angioedema

Linguistic Adaptation of Urticaria Activity Score Over 7 Days (UAS7) to Latvian: Evaluating Disease Activity in Adult Patients with Chronic Spontaneous Urticaria in Latvia

Paradoxical urticaria to H1-antihistamines in a patient with chronic spontaneous urticaria

Urticaria activity, quality of life and disease control in chronic spontaneous urticaria patients in Kazakhstan

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study

Features of chronic spontaneous urticaria in patients with atopic comorbidities: Results from CURE, the chronic urticaria registry

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Sponsored Symposia

Event Resources

Position Papers

Guidelines

Covid-19

Website

Sessions

News